# Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

> **NCT02698111** · PHASE1,PHASE2 · TERMINATED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 20 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Donafenib

## Key facts

- **NCT ID:** NCT02698111
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-08
- **Primary completion:** 2021-10-20
- **Final completion:** 2021-10-20
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Corporate policy adjustments
- **Last updated:** 2023-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02698111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02698111, "Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02698111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*